Duration of Previous Treatment as a Prognostic Factor in Metastatic Colorectal Cancer Treated With Trifluridine/Tipiracil

Molecular and Clinical Oncology - United Kingdom
doi 10.3892/mco.2018.1600
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

Real‐World Adherence in Patients With Metastatic Colorectal Cancer Treated With Trifluridine Plus Tipiracil or Regorafenib

Oncologist
Cancer ResearchMedicineOncology
2019English

Cost Effectiveness of Trifluridine/Tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales

Clinical Colorectal Cancer
OncologyGastroenterology
2018English

Real-World Treatment Patterns Among Patients With Colorectal Cancer Treated With Trifluridine/Tipiracil and Regorafenib

Clinical Colorectal Cancer
OncologyGastroenterology
2018English

A Retrospective Study of Trifluridine/Tipiracil in Pretreated Metastatic Colorectal Cancer Patients in Clinical Practice

Colorectal Cancer
OncologyGastroenterology
2018English

Emerging Combination Therapies for Metastatic Colorectal Cancer &Ndash; Impact of Trifluridine/Tipiracil

Cancer Management and Research
Oncology
2017English

Review of Metastatic Colorectal Cancer Treatment Pathways and Early Clinical Experience of Trifluridine/Tipiracil in the UK Named Patient Programme

BMC Cancer
Cancer ResearchOncologyGenetics
2020English

Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of Two Randomized Clinical Trials

Clinical Colorectal Cancer
OncologyGastroenterology
2018English

Trifluridine/Tipiracil: Old Drug, New Tricks

Journal of the Advanced Practitioner in Oncology
2016English

Carcinoembryonic Antigen as a Prognostic Factor in Colorectal Cancer With Liver Metastases

Journal of Cancer Therapy
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy